Cargando…

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results

Ibrutinib has revolutionized the treatment of chronic lymphocytic leukemia (CLL). This drug irreversibly inhibits Bruton tyrosine kinase (BTK) by covalently binding to the C481 residue in the BTK kinase domain. BTK is a pivotal protein for B cell receptor signaling and tissue homing of CLL cells. Pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Timofeeva, Natalia, Gandhi, Varsha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085243/ https://www.ncbi.nlm.nih.gov/pubmed/33927183 http://dx.doi.org/10.1038/s41408-021-00467-7

Ejemplares similares

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib
por: Nakhoda, Shazia, et al.
Publicado: (2023)

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations
por: Lovell, Alexandra R., et al.
Publicado: (2022)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Davis, Joanne E., et al.
Publicado: (2021)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
por: Mascolo, Annamaria, et al.
Publicado: (2023)

FIRE Study: Real-World Effectiveness and Safety of Ibrutinib in Clinical Practice in Patients with CLL and MCL
por: Dartigeas, Caroline, et al.
Publicado: (2022)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
por: Kazianka, L, et al.
Publicado: (2017)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells
por: Chowdhury, Subir Roy, et al.
Publicado: (2021)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
por: Reda, Gianluigi, et al.
Publicado: (2018)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Ibrutinib Is Associated With Increased Cardiovascular Events and Major Bleeding in Older CLL Patients
por: Diamond, Akiva, et al.
Publicado: (2023)

PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
por: Qerama, Shaqir, et al.
Publicado: (2023)

Curing CLL: one clone at a time
por: Aslan, Burcu, et al.
Publicado: (2022)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017)

Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort
por: Reda, Gianluigi, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
por: Jain, Nitin, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Ibrutinib in the Treatment of CLL Patients: A Real Life Experience
por: Broccoli, Alessandro, et al.
Publicado: (2021)

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL
por: Rendeiro, André F., et al.
Publicado: (2020)

Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance
por: Omi, Ai, et al.
Publicado: (2022)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
por: Mahlich, Jörg, et al.
Publicado: (2017)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLL12 TRIAL
por: Langerbeins, Petra, et al.
Publicado: (2023)

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

A first case of successful using of ibrutinib in treating paraneoplastic pemphigus related bronchiolitis obliterans concurrent with CLL
por: Chen, Can, et al.
Publicado: (2023)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Critical molecular pathways in CLL therapy
por: Ferrer, Gerardo, et al.
Publicado: (2018)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study
por: Deering, Kathleen L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rqboegrudsifpubgqa1vhn0r1d